GE HealthCare (GEHC) will be an industry lead in COMPASS, a five-year European consortium focused on improving early detection and management of cardiovascular risks in cancer patients.
The consortium has a total budget of €50.5 million and more than 60 partners. It aims to address cardiovascular health through earlier detection of cardiotoxicity, AI-enabled clinical decision support, and improved long-term cardiovascular follow-up for oncology patients.
The consortium was co-funded under the EU's Horizon Europe framework as part of the Innovative Health Initiative (IHI) and was formalized with a grant agreement signed on 25 March; it will run through 2031. King's College London will provide academic leadership and scientific coordination, the company said.
COMPASS research will focus on three areas:
- Identification of novel biomarkers for cardiotoxicity diagnosis and risk stratification, including molecular imaging and multi-omics approaches.
- AI-enabled predictive and clinical decision-support tools integrating imaging, biomarker, and wearable data.
- Improved care delivery and patient engagement to support long-term cardiovascular follow-up in oncology patients.
